vs
富兰克林电气（FELE）与Pediatrix Medical Group, Inc.（MD）财务数据对比。点击上方公司名可切换其他公司
富兰克林电气的季度营收约是Pediatrix Medical Group, Inc.的1.0倍（$500.4M vs $493.8M），富兰克林电气净利率更高（6.9% vs 6.8%，领先0.1%），富兰克林电气同比增速更快（9.9% vs -1.7%），过去两年Pediatrix Medical Group, Inc.的营收复合增速更高（-0.1% vs -4.0%）
富兰克林电气是全球知名的水务与能源管理产品及系统制造分销商，主营泵类、电机、驱动器及控制设备，产品广泛应用于住宅、商用、农业、工业、市政等多元场景。公司总部位于美国印第安纳州韦恩堡，在美国、德国、捷克、意大利、土耳其、墨西哥、巴西、澳大利亚、南非等多个国家设有生产基地，为全球客户提供可靠的流体运输与能源管理解决方案。
Pediatrix Medical Group是美国领先的专科医疗服务提供商，核心业务覆盖母胎医学、新生儿科、儿科心脏病学等儿科亚专科领域，与美国各地医疗机构合作，为女性、新生儿及儿童提供循证专科医疗服务。
FELE vs MD — 直观对比
营收规模更大
FELE
是对方的1.0倍
$493.8M
营收增速更快
FELE
高出11.6%
-1.7%
净利率更高
FELE
高出0.1%
6.8%
两年增速更快
MD
近两年复合增速
-4.0%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $500.4M | $493.8M |
| 净利润 | $34.7M | $33.7M |
| 毛利率 | 35.0% | — |
| 营业利润率 | 9.6% | 9.9% |
| 净利率 | 6.9% | 6.8% |
| 营收同比 | 9.9% | -1.7% |
| 净利润同比 | 10.6% | 10.5% |
| 每股收益（稀释后） | $0.77 | $0.40 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FELEMD
| Q1 26 | $500.4M | — | ||
| Q4 25 | $506.9M | $493.8M | ||
| Q3 25 | $581.7M | $492.9M | ||
| Q2 25 | $587.4M | $468.8M | ||
| Q1 25 | $455.2M | $458.4M | ||
| Q4 24 | $485.7M | $502.4M | ||
| Q3 24 | $531.4M | $511.2M | ||
| Q2 24 | $543.3M | $504.3M |
净利润FELEMD
| Q1 26 | $34.7M | — | ||
| Q4 25 | $39.3M | $33.7M | ||
| Q3 25 | $16.7M | $71.7M | ||
| Q2 25 | $60.1M | $39.3M | ||
| Q1 25 | $31.0M | $20.7M | ||
| Q4 24 | $33.7M | $30.5M | ||
| Q3 24 | $54.6M | $19.4M | ||
| Q2 24 | $59.1M | $-153.0M |
毛利率FELEMD
| Q1 26 | 35.0% | — | ||
| Q4 25 | 33.8% | — | ||
| Q3 25 | 35.9% | — | ||
| Q2 25 | 36.1% | — | ||
| Q1 25 | 36.0% | — | ||
| Q4 24 | 33.8% | — | ||
| Q3 24 | 35.7% | — | ||
| Q2 24 | 36.8% | — |
营业利润率FELEMD
| Q1 26 | 9.6% | — | ||
| Q4 25 | 10.2% | 9.9% | ||
| Q3 25 | 14.6% | 13.8% | ||
| Q2 25 | 15.0% | 12.8% | ||
| Q1 25 | 9.7% | 7.0% | ||
| Q4 24 | 8.9% | 7.8% | ||
| Q3 24 | 13.8% | 6.6% | ||
| Q2 24 | 14.6% | -31.3% |
净利率FELEMD
| Q1 26 | 6.9% | — | ||
| Q4 25 | 7.7% | 6.8% | ||
| Q3 25 | 2.9% | 14.5% | ||
| Q2 25 | 10.2% | 8.4% | ||
| Q1 25 | 6.8% | 4.5% | ||
| Q4 24 | 6.9% | 6.1% | ||
| Q3 24 | 10.3% | 3.8% | ||
| Q2 24 | 10.9% | -30.3% |
每股收益（稀释后）FELEMD
| Q1 26 | $0.77 | — | ||
| Q4 25 | $0.87 | $0.40 | ||
| Q3 25 | $0.37 | $0.84 | ||
| Q2 25 | $1.31 | $0.46 | ||
| Q1 25 | $0.67 | $0.24 | ||
| Q4 24 | $0.73 | $0.37 | ||
| Q3 24 | $1.17 | $0.23 | ||
| Q2 24 | $1.26 | $-1.84 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $80.4M | $375.2M |
| 总债务越低越好 | $134.4M | $570.5M |
| 股东权益账面价值 | $1.3B | $865.9M |
| 总资产 | $2.0B | $2.2B |
| 负债/权益比越低杠杆越低 | 0.10× | 0.66× |
8季度趋势，按日历期对齐
现金及短期投资FELEMD
| Q1 26 | $80.4M | — | ||
| Q4 25 | $99.7M | $375.2M | ||
| Q3 25 | $102.9M | $340.1M | ||
| Q2 25 | $104.6M | $224.7M | ||
| Q1 25 | $84.0M | $99.0M | ||
| Q4 24 | $220.5M | $229.9M | ||
| Q3 24 | $106.3M | $103.8M | ||
| Q2 24 | $58.1M | $19.4M |
总债务FELEMD
| Q1 26 | $134.4M | — | ||
| Q4 25 | $135.2M | $570.5M | ||
| Q3 25 | $135.2M | $577.2M | ||
| Q2 25 | $14.5M | $583.9M | ||
| Q1 25 | $14.9M | $590.5M | ||
| Q4 24 | $11.6M | $597.1M | ||
| Q3 24 | $11.6M | — | ||
| Q2 24 | $87.2M | — |
股东权益FELEMD
| Q1 26 | $1.3B | — | ||
| Q4 25 | $1.3B | $865.9M | ||
| Q3 25 | $1.3B | $890.7M | ||
| Q2 25 | $1.3B | $833.8M | ||
| Q1 25 | $1.3B | $789.2M | ||
| Q4 24 | $1.3B | $764.9M | ||
| Q3 24 | $1.3B | $732.5M | ||
| Q2 24 | $1.2B | $706.5M |
总资产FELEMD
| Q1 26 | $2.0B | — | ||
| Q4 25 | $1.9B | $2.2B | ||
| Q3 25 | $2.0B | $2.2B | ||
| Q2 25 | $2.0B | $2.1B | ||
| Q1 25 | $1.9B | $2.0B | ||
| Q4 24 | $1.8B | $2.2B | ||
| Q3 24 | $1.8B | $2.1B | ||
| Q2 24 | $1.8B | $2.0B |
负债/权益比FELEMD
| Q1 26 | 0.10× | — | ||
| Q4 25 | 0.10× | 0.66× | ||
| Q3 25 | 0.10× | 0.65× | ||
| Q2 25 | 0.01× | 0.70× | ||
| Q1 25 | 0.01× | 0.75× | ||
| Q4 24 | 0.01× | 0.78× | ||
| Q3 24 | 0.01× | — | ||
| Q2 24 | 0.07× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $114.1M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | 3.39× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流FELEMD
| Q1 26 | — | — | ||
| Q4 25 | $104.2M | $114.1M | ||
| Q3 25 | $102.7M | $137.3M | ||
| Q2 25 | $51.5M | $137.2M | ||
| Q1 25 | $-19.5M | $-117.5M | ||
| Q4 24 | $110.3M | $133.0M | ||
| Q3 24 | $116.1M | $91.8M | ||
| Q2 24 | $36.4M | $107.0M |
自由现金流FELEMD
| Q1 26 | — | — | ||
| Q4 25 | $88.7M | — | ||
| Q3 25 | $91.3M | — | ||
| Q2 25 | $39.9M | — | ||
| Q1 25 | $-26.3M | — | ||
| Q4 24 | $97.5M | — | ||
| Q3 24 | $106.6M | — | ||
| Q2 24 | $26.1M | — |
自由现金流率FELEMD
| Q1 26 | — | — | ||
| Q4 25 | 17.5% | — | ||
| Q3 25 | 15.7% | — | ||
| Q2 25 | 6.8% | — | ||
| Q1 25 | -5.8% | — | ||
| Q4 24 | 20.1% | — | ||
| Q3 24 | 20.1% | — | ||
| Q2 24 | 4.8% | — |
资本支出强度FELEMD
| Q1 26 | — | — | ||
| Q4 25 | 3.1% | — | ||
| Q3 25 | 2.0% | — | ||
| Q2 25 | 2.0% | — | ||
| Q1 25 | 1.5% | — | ||
| Q4 24 | 2.6% | — | ||
| Q3 24 | 1.8% | — | ||
| Q2 24 | 1.9% | — |
现金转化率FELEMD
| Q1 26 | — | — | ||
| Q4 25 | 2.65× | 3.39× | ||
| Q3 25 | 6.14× | 1.91× | ||
| Q2 25 | 0.86× | 3.49× | ||
| Q1 25 | -0.63× | -5.66× | ||
| Q4 24 | 3.28× | 4.36× | ||
| Q3 24 | 2.13× | 4.72× | ||
| Q2 24 | 0.62× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FELE
暂无分部数据
MD
| Health Care Patient Service | $421.6M | 85% |
| Hospitals Contracts | $70.0M | 14% |
| Other | $2.2M | 0% |
